A	B	C	D	E	F	G	H	I	J	K	L	M
1
2		Brand	Generic	Indication	MOA	Approved	Economics	IP			Price	219.94
3		Brukinsa	zanubrutinib	MCL, WM, MZL	BTK		100%?				Shares	103.8184753846154	Q322
4			tislelizumab	eSCC	PD-1	China	NVS				MC	22833.83547609231
5		Blincyto	blinatumomab				AMGN				Cash	5069.129999999999	Q322
6		Kyprolis					AMGN				Debt	649.275	Q322
7		Pobevcy									EV	18413.980476092314
8		Revlimid					BMY
9						Phase					6160 HK
10			ociperlimab		TIGIT		NVS				688235 CH
11		BGB-A445			OX40 mab
12			pamiparib								Global Head of R&D: Lai Wang
13		BGB-15025			HPK1 inhibitor
14		LBL-007			LAG-3
15		BGB-11417			BCL-2
16		BGB-10188			PI3Kdelta inhibitor
17		BGB-16673			BTK Protac
18			zanidatamab		HER2 mab
19		BGB-23339			TYK2 inhibitor